N
OLMA icon

Nuveen’s Olema Pharmaceuticals OLMA Stock Holding History

Nuveen’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.16M Buy
278,990
+49,521
+22% +$1.1M ﹤0.01% 1959
2025
Q4 		$5.74M Buy
229,469
+101,249
+79% +$1.8M ﹤0.01% 1847
2025
Q3 		$1.26M Hold
128,220
– – ﹤0.01% 2514
2025
Q2 		$546K Sell
128,220
-216,076
-63% -$963K ﹤0.01% 2861
2025
Q1 		$1.29M Buy
344,296
+225,862
+191% +$1.14M ﹤0.01% 2518
2024
Q4 		$690K Hold
118,434
– – ﹤0.01% 2865
2024
Q3 		$1.41M Hold
118,434
– – ﹤0.01% 2596
2024
Q2 		$1.28M Buy
118,434
+17,545
+17% +$190K ﹤0.01% 2605
2024
Q1 		$1.14M Hold
100,889
– – ﹤0.01% 2643
2023
Q4 		$1.42M Buy
100,889
+394
+0.4% +$5.29K ﹤0.01% 2573
2023
Q3 		$1.24M Buy
100,495
+45
+0% +$459 ﹤0.01% 2485
2023
Q2 		$907K Buy
+100,450
New +$606K ﹤0.01% 2702
2022
Q2 		– Sell
-437,425
Closed -$2.13M – 3421
2022
Q1 		$2.13M Buy
437,425
+147,982
+51% +$815K ﹤0.01% 2475
2021
Q4 		$2.52M Sell
289,443
-8,059
-3% -$167K ﹤0.01% 2456
2021
Q3 		$8.15M Buy
297,502
+249,727
+523% +$6.74M ﹤0.01% 1919
2021
Q2 		$1.34M Buy
47,775
+3,579
+8% +$102K ﹤0.01% 2888
2021
Q1 		$1.47M Buy
+44,196
New +$1.89M ﹤0.01% 2752

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Nuveen's OLMA Position: Q1 2026 in Review

Nuveen increased its Olema Pharmaceuticals (OLMA) stake by 22% in Q1 2026, buying an estimated $1.1M and bringing the position to 278,990 shares worth $4.16M. The position accounts for ﹤0.01% of the portfolio, ranked #1959.

Nuveen first reported a position in OLMA in Q1 2021 and has held it in 17 quarters since. The position peaked at $8.15M in Q3 2021. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Nuveen held 278,990 shares of Olema Pharmaceuticals worth $4.16M as of Q1 2026.
  • Nuveen bought 49,521 Olema Pharmaceuticals shares in Q1 2026, an estimated $1.1M.
  • Olema Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1959 holding.
  • Nuveen first reported a position in Olema Pharmaceuticals in Q1 2021 and has held it in 17 quarters since.
  • Nuveen's Olema Pharmaceuticals position peaked at $8.15M in Q3 2021.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.